Academic Journals Database
Disseminating quality controlled scientific knowledge

T-SPOT.TB responses during treatment of pulmonary tuberculosis

ADD TO MY LIST
 
Author(s): Ribeiro Samantha | Dooley Kelly | Hackman Judith | Loredo Carla | Efron Anne | Chaisson Richard | Conde Marcus | Boechat Neio | Dorman Susan

Journal: BMC Infectious Diseases
ISSN 1471-2334

Volume: 9;
Issue: 1;
Start page: 23;
Date: 2009;
Original page

ABSTRACT
Abstract Background Immune responses to Mycobacterium tuberculosis antigens could serve as surrogate markers of treatment response. Methods Using the T-SPOT.TB assay and frozen peripheral blood mononuclear cells, we enumerated ESAT-6- and CFP-10-specific IFN-γ-producing T cells over time in pulmonary TB patients receiving directly observed treatment. T cell responses (measured as "spot forming cells" or "SFCs") were assessed prior to treatment and at 16 and 24 weeks of treatment. Results 58 patients were evaluated, of whom 57 were HIV seronegative. Mean (SD) ESAT-6, CFP-10, and summed RD1 specific SFCs declined from 42.7 (72.7), 41.2 (66.4), and 83.8 (105.7) at baseline to 23.3 (39.4, p = 0.01), 23.2 (29.4, p = 0.18), and 46.5 (59.5, p = 0.02) at completion of 24 weeks of treatment, respectively. Only 10% of individuals with a baseline reactive test reverted to negative at treatment week 24. For the group that was culture positive at completion of 8 weeks of treatment compared to the culture negative group, the incidence rate ratio (IRR) of ESAT-6, CFP-10, and summed RD1 specific SFC counts were, respectively, 2.23 (p = 0.048), 1.51 (p = 0.20), and 1.83 (p = 0.047). Patients with cavitary disease had mean ESAT-6 specific SFC counts that were higher than those without cavitary disease (IRR 2.08, p = 0.034). Conclusion IFN-γ-producing RD1-specific T cells, as measured in the T-SPOT.TB assay, may be directly related to bacterial load in patients undergoing treatment for pulmonary TB. However, high inter-subject variability in quantitative results coupled with failure of reversion to negative of qualitative results in most subjects at treatment completion may limit the utility of this assay as a surrogate marker for treatment efficacy.
Why do you need a reservation system?      Save time & money - Smart Internet Solutions